CHRS Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting gr…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts. | ||
 Coherus Oncology, Inc. Q2 2026 Earnings Call Summary Moby summary of Coherus Oncology, Inc.'s Q2 2026 earnings call | ||
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... Coherus Oncology Inc (CHRS) reports 15% LOQTORZI sales growth and advancing oncology pipeline, while managing significant cash reduction and legacy liabilities. | ||
 Coherus Oncology Q2 Earnings Call Highlights Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. Chief Executive Officer Denny Lanfear said | ||
 Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||